DATATRAK International, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012; Appoints James M. Karis to its Board
May 09, 2012 at 07:30 am EDT
Share
DATATRAK International, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the period, the company reported net loss of $516,800 or $0.04 per basic and diluted share on revenue of $2,119,198 against net loss of $200,453 or $0.01 per basic and diluted share on revenue of $1,888,321 a year ago. Loss from operations was $515,277 compared to $197,959 a year ago. Interest income was $132 compared to $180 a year ago.
The company announced that on May 8, 2012, its Board of Directors appointed James M. Karis as a Director to its Board. Mr. Karis is the CEO of CollabRx, Inc.
Datatrak International, Inc. is a technology and services company. The Company is engaged in delivering global eClinical solutions for the clinical trials industry. The Company is focused on providing subscription and professional services. Its enterprise platforms include Decentralized Trials (including, electronic consent (e-Consent), electronic patient reported outcomes (e-PRO) and electronic clinical outcomes assessment (e-COA), electronic data capture, clinical trial management system (CTMS) and imaging and endpoint adjudication, randomization, and business intelligence. The Companyâs CTMS includes functions for site feasibility and the tracking of action items and milestones. Its imaging and endpoint adjudication is a streamline the approach for managing imaging components while reducing manual workload and errors. Its business intelligence offers solution to create, monitor, and analyze user research and providing insights that allow to optimize processes from all aspects.
DATATRAK International, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012; Appoints James M. Karis to its Board
DATATRAK INTERNATIONAL, INC. 